DOXEPIN HYDROCHLORIDE

Post-LOE

doxepin hydrochloride

Jubilant Therapeutics

ANDAORALCAPSULE

Approved

Mar 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXEPIN HYDROCHLORIDE (doxepin hydrochloride) by Jubilant Therapeutics is understood. Approved for major depressive disorder (mdd) in adults ( ). First approved in 2022.

Drug data last refreshed 1w ago

Mechanism of Action

understood.

Indications (1)

major depressive disorder (MDD) in adults ( )

Clinical Trials (1)

NCT01156142Phase 3Completed

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Started Dec 2010

155 enrolled

Head and Neck CancerMucositisOral Complications of Radiation Therapy+1 more

Company

Worked on DOXEPIN HYDROCHLORIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.